The 3-year OS rates for patients with ALK + ALCL (82.5%) and ALK − ALCL (68.2%) were significantly higher than the rates for patients with other subtypes (36.6% for AITL, 40.0% for PTCL-NOS and other subtypes, p < 0.001; Fig. 2b). This evidence concerns the gene ALK and anaplastic large cell lymphoma.